Imperial College London
Alternate

DrDeborahMorris-Rosendahl

Faculty of Medicine, National Heart & Lung Institute

Honorary Senior Research Fellow
 
 
 
//

Contact

 

+44 (0)20 7351 8412d.morris-rosendahl

 
 
//

Location

 

2091Royal BromptonRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Sepahzad:2021:10.3390/genes12040562,
author = {Sepahzad, A and Morris-Rosendahl, D and Davies, J},
doi = {10.3390/genes12040562},
journal = {Genes},
title = {Cystic fibrosis lung disease modifiers and their relevance in the new era of precision medicine},
url = {http://dx.doi.org/10.3390/genes12040562},
volume = {12},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Our understanding of cystic fibrosis (CF) has grown exponentially since the discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in 1989. With evolving genetic and genomic tools, we have come to better understand the role of CFTR genotypes in the pathophysiology of the disease. This, in turn, has paved the way for the development of modulator therapies targeted at mutations in the CFTR, which are arguably one of the greatest advances in the treatment of CF. These modulator therapies, however, do not target all the mutations in CFTR that are seen in patients with CF and, furthermore, a variation in response is seen in patients with the same genotype who are taking modulator therapies. There is growing evidence to support the role of non-CFTR modifiers, both genetic and environmental, in determining the variation seen in CF morbidity and mortality and also in the response to existing therapies. This review focusses on key findings from studies using candidate gene and genome-wide approaches to identify CF modifier genes of lung disease in cystic fibrosis and considers the interaction between modifiers and the response to modulator therapies. As the use of modulator therapies expands and we gain data around outcomes, it will be of great interest to investigate this interaction further. Going forward, it will also be crucial to better understand the relative influence of genomic versus environmental factors. With this understanding, we can truly begin to deliver personalised care by better profiling the likely disease phenotype for each patient and their response to treatment.
AU  - Sepahzad,A
AU  - Morris-Rosendahl,D
AU  - Davies,J
DO  - 10.3390/genes12040562
PY  - 2021///
SN  - 2073-4425
TI  - Cystic fibrosis lung disease modifiers and their relevance in the new era of precision medicine
T2  - Genes
UR  - http://dx.doi.org/10.3390/genes12040562
UR  - http://hdl.handle.net/10044/1/89232
VL  - 12
ER  -
Download